TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27664217
Drug: Immediate insertion
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate insertion of etonogestrel releasing implant (inserted 1 hour after mifepristone intake)
Study: 27664217
Drug: Routine insertion
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine insertion of etonogestrel releasing implant (inserted at follow-up 2-4 weeks later)
Study: 27664217
Drug: Immediate insertion
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate insertion of etonogestrel releasing implant
Study: 27664217
Drug: Routine insertion
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine insertion of etonogestrel releasing implant
Study: 22935338
Drug: Quercetin (Q)
DrugBank: Quercetin (DB04216)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin (Q) 1095 mg
Study: 19011774
Drug: 1.2 ml
Normalized name: Mozobil 24 MG in 1.2 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 ml (6 mg) of 0.5% hyperbaric bupivacaine with 0.16 mg of morphine (group BM)
Study: 19011774
Drug: 1.2 ml
Normalized name: Mozobil 24 MG in 1.2 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 ml (6 mg) of 0.5% hyperbaric bupivacaine (group B)
Study: 10984265
Drug: subcutaneous octreotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous octreotide
Study: 3099490
Drug: Transdermally applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermally applied nitroglycerin (TDS) 5.0 mg in 24 hours
Study: 3099490
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release nitroglycerin capsules (NTR) 2.5 mg
Study: 29301785
Drug: Intensive lipid
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive lipid therapy (LDL-C <70 mg/dL)
Study: 24593225
Drug: Pomegranate juice
Normalized name: pomegranate juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomegranate juice (PJ) 100 cc, 0.7 mM polyphenols, three times a week for one year
Study: 18925346
Drug: Specialized behavioral
Normalized name: epinephrine / mepivacaine hydrochloride Injectable Solution [Scandonest 2% Special]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specialized behavioral therapy + placebo + medical management
Study: 18925346
Drug: Specialized behavioral
Normalized name: epinephrine / mepivacaine hydrochloride Injectable Solution [Scandonest 2% Special]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specialized behavioral therapy alone
Study: 12638641
Drug: 5-HT-selective pharmacotherapy
Normalized name: 5-HT
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-HT-selective pharmacotherapy
Study: 9827783
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin sodium with a 5‐day hospitalization
Study: 9827783
Drug: Ardeparin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ardeparin and Unfractionated heparin
Study: 29209778
Drug: Prourokinase injection
Normalized name: urokinase Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prourokinase injection (20 mg intravenously followed by 30 mg intravenous infusion within 30 min)
Study: 29209778
Drug: Prourokinase injection
Normalized name: urokinase Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prourokinase injection
Study: 25129820
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no intravenous metoprolol)
Study: 9154893
Drug: Inhaled leukotriene
Normalized name: Leukotriene D4
DrugBank: Leukotriene D4 (DB11858)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled leukotriene B4 (17.6 +/- 3.4 microg for normal subjects; 18.2 +/- 1.9 microg for asthmatics)
Study: 4074450
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg proglumetacin t.i.d.
Study: 4074450
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg indometacin t.i.d.
Study: 24635880
Drug: 3-monthly monitoring
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 3-monthly monitoring
Study: 24635880
Drug: 6-monthly monitoring
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 6-monthly monitoring
Study: 24635880
Drug: Cost-effectiveness of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cost-effectiveness of 6-monthly monitoring
Study: 22128444
Drug: Epidural steroid/local
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural steroid/local anesthetic injection (Group 2)
Study: 17927726
Drug: Intramuscular route
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular route (Group 1): ketamine (6 mg/kg), midazolam (0.05 mg/kg), atropine (0.02 mg/kg)
Study: 17927726
Drug: Oral route
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral route (Group 2): ketamine (10 mg/kg), midazolam (0.2 mg/kg), atropine (0.05 mg/kg)
Study: 15105231
Drug: Morphine 100
Normalized name: MORPHINE 100MG/NALTREXONE 4MG SA CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 100 microg
Study: 15321310
Drug: Fentanyl 25
Normalized name: FENTANYL 25MCG/HR PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 25 microg and Morphine 100 microg
Study: 2027118
Drug: Nonsteroidal anti-inflammatory
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsteroidal anti-inflammatory drug
Study: 31599468
Drug: Sequential Multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential Multiple Assignment Randomized Trial (SMART) design
Study: 23509932
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care group (standard early oral health screening program; 'lift the lip')
Study: 21786489
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of normal saline
Study: 19078947
Drug: Calcium channel
Normalized name: Calcium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium channel alpha2delta ligands (lead compound at approximately 30 mg)
Study: 19078947
Drug: Calcium channel
Normalized name: Calcium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium channel alpha2delta ligands (backup compound at >600 mg)
Study: 16877536
Drug: Cluster of
Normalized name: Cluster of differentiation 45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cluster of three IRS-related conditions (hypertension, BMI >/=25 kg/m(2), HDL cholesterol <40 mg/dl)
Study: 17609247
Drug: Mifepristone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone (5 mg daily)
Study: 17609247
Drug: Levonorgestrel (0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levonorgestrel (0.03 mg progestogen-only pill)
Study: 17609247
Drug: Mifepristone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone (5 mg daily) with condoms
Study: 16216596
Drug: DASH diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: DASH diet rich in fruits, vegetables and low-fat dairy products, reduced in fat (27%), saturated fat (7%), and cholesterol (150 mg/day) for 3 months
Study: 12220692
Drug: Polish patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polish patients on aspirin before stroke
Study: 8120559
Drug: Intravenous ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ondansetron plus dexamethasone
Study: 8120559
Drug: Intravenous ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ondansetron alone
Study: 31290715
Drug: 13-valent pneumococcal
Normalized name: Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine
DrugBank: Streptococcus pneumoniae type 14 capsular polysaccharide diphtheria CRM197 protein conjugate antigen (DB10289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13-valent pneumococcal conjugated vaccine (PCV13)
Study: 30215583
Drug: 23-valent pneumococcal
Normalized name: Streptococcus pneumoniae type 1 capsular polysaccharide antigen
DrugBank: Streptococcus pneumoniae type 1 capsular polysaccharide antigen (DB10319)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23-valent pneumococcal polysaccharide vaccine (PPV23)
Study: 31290715
Drug: Both vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both vaccines (PPV23 and PCV13)
Study: 24385202
Drug: Anti-TNFα therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TNFα therapy (infliximab and etanercept)
Study: 21469401
Drug: Chemomechanical (papain‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemomechanical (papain‐based gel followed by curette)
Study: 3138446
Drug: OpSite dressings
Normalized name: DRESSING,OPSITE
Approvals — FDA: no, EMA: no, PMDA: no
Description: OpSite dressings changed twice weekly (OpS-ICU)
Study: 19602839
Drug: BCAA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCAA supplementation (isoleucine:leucine:valine=1:2.3:1.2) at 0.1 g/kg body weight 15 min before squat exercise
Study: 19602839
Drug: Placebo (dextrin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (dextrin) at 0.1 g/kg body weight 15 min before squat exercise
Study: 14678375
Drug: Intravesical prostaglandin
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical prostaglandin E2 (1.5 mg in 20 mL 0.9% saline) plus oral bethanechol chloride (50 mg four times daily) for 6 weeks
Study: 14678375
Drug: Saline instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline instillation plus placebo tablets for 6 weeks
Study: 10210973
Drug: Two nucleoside
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two nucleoside analogues and one protease inhibitor
Study: 7596211
Drug: Continuous treatment
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous treatment teams with extensive training in in vivo treatment
Study: 7596211
Drug: Case management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Case management program emphasizing office-based treatment
Study: 656357
Drug: Pilocarpine in
Normalized name: Product containing pilocarpine in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pilocarpine in an oily solution
Study: 656357
Drug: Pilocarpine in
Normalized name: Product containing pilocarpine in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pilocarpine in aqueous solution
Study: 6797663
Drug: Alternative drugs
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative drugs (specific drugs not mentioned)
Study: 6797663
Drug: Treatment-free interval
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-free interval between drugs
Study: 6797663
Drug: Gold, penicillamine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gold, penicillamine, levamisole (as first second-line drug)
Study: 25701002
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg DHA
Study: 19568197
Drug: L‐arginine hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐arginine hydrochloride capsules (7.2 g x d(‐1))
Study: 10409565
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (0.3 g/kg/day for 5 days)
Study: 2155697
Drug: Maintenance chemotherapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance chemotherapy (four cycles) after radiotherapy
Study: 2155697
Drug: Initial chemotherapy
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial chemotherapy (vindesine-cisplatin)
Study: 2155697
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment (chemotherapy followed by radiotherapy)
Study: 31868149
Drug: Nanocurcumin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nanocurcumin (40 mg capsule every 12 hours for six weeks)
Study: 31868149
Drug: Placebo (similar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (similar components of nanomicelle curcumin capsules without curcumin)
Study: 27533333
Drug: 24% sucrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24% sucrose solution administered orally 2 minutes prior to PIV catheter insertion
Study: 27533333
Drug: Placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution administered orally 2 minutes prior to PIV catheter insertion
Study: 23111980
Drug: Remogliflozin etabonate
Normalized name: Remogliflozin etabonate
DrugBank: Remogliflozin etabonate (DB12935)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remogliflozin etabonate (RE) 100 mg administered to the mid‐small intestine
Study: 23111980
Drug: Remogliflozin etabonate
Normalized name: Remogliflozin etabonate
DrugBank: Remogliflozin etabonate (DB12935)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remogliflozin etabonate (RE) 100 mg administered to the large intestine
Study: 23111980
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of the IR tablet of RE
Study: 17086074
Drug: Tinnitus-coping therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinnitus-coping therapy (TCT) with TCI provision
Study: 17086074
Drug: Tinnitus-coping therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinnitus-coping therapy (TCT) without TCI devices
Study: 17086074
Drug: Waiting-list control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waiting-list control group (no treatment for 12 months)
Study: 9863541
Drug: Pravastatin 40
Normalized name: pravastatin 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 40 mg nocte
Study: 8574712
Drug: Human recombinant
Normalized name: Human recombinant AP
DrugBank: Recombinant human alkaline phosphatase (DB17672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human recombinant EGF administered subcutaneously
Study: 313873
Drug: 5-fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (5-FU) in combination with intramuscularly administered C. parvum
Study: 31364896
Drug: Augmented biofeedback
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmented biofeedback training and physical therapy (Group C)
Study: 31364896
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy (Group A)
Study: 26837463
Drug: 40-mg oral
Normalized name: estradiol 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40-mg oral atomoxetine
Study: 23469599
Drug: Yiqi Fumai
Normalized name: Aspergillus fumigatus allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yiqi Fumai Injection (YFI) alone, 2.6 g YFI in 250 mL normal saline, once daily for 15 days
Study: 23469599
Drug: Hydroxychloroquine sulfate
Normalized name: Hydroxychloroquine Sulfate
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine sulfate alone, 0.2 g twice daily for 15 days
Study: 23469599
Drug: Yiqi Fumai
Normalized name: Aspergillus fumigatus allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yiqi Fumai Injection (YFI) combined with hydroxychloroquine sulfate, same dosages as Groups A and B for 15 days
Study: 20203451
Drug: Multiple risk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple risk factor intervention strategy based on single‐pill amlodipine besylate/atorvastatin calcium
Study: 18790313
Drug: Cognitive behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behaviour therapy-based intervention delivered by trained primary health workers
Study: 15863377
Drug: Tamoxifen (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (10 mg per day for 24 weeks)
Study: 15863377
Drug: Bicalutamide alone
Normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bicalutamide alone (150 mg per day)
Study: 12002672
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg Ginkgo biloba extract twice daily for 7 days
Study: 12002672
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg Ginkgo biloba extract once daily for 7 days
Study: 8983868
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid infusion (19 amino acids, 240 kJ/h)
Study: 8983868
Drug: Control (isovolumic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (isovolumic infusions of nutrient-free saline solution)
Study: 1744992
Drug: Sulphadimidine 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulphadimidine 250 mg
Study: 1744992
Drug: Sulphadimidine 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulphadimidine 500 mg
Study: 1744992
Drug: Sulphadimidine 750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulphadimidine 750 mg
Study: 1744992
Drug: Sulphadimidine 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulphadimidine 1000 mg
Study: 1744992
Drug: Initial oral
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial oral dose of 750 mg
Study: 31377284
Drug: Teprotumumab (fully
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teprotumumab (fully human monoclonal IGF‐1R antagonist antibody)
Study: 30382734
Drug: Juvenile Justice
Normalized name: Justicia spicigera leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Juvenile Justice Anger Management (JJAM) Treatment
Study: 17040483
Drug: Immediate periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate periodontal therapy (early treatment)
Study: 17040483
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care followed by periodontal therapy (deferred treatment)
Study: 16232154
Drug: MIG-99 (6.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: MIG-99 (6.25 mg t.i.d.)
Study: 7780891
Drug: Ofloxacin drops
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ofloxacin drops (0.3% solution, 10 drops)
Study: 7780891
Drug: Tobramycin drops
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tobramycin drops (0.3% solution, 10 drops) with erythromycin ointment post-surgery
Study: 21504616
Drug: Fluconazole in
Normalized name: fluconazole Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole in situ gels (0.5% w/v) for 14 days
Study: 21504616
Drug: Fluconazole tablets
Normalized name: Fluconazole Tablets
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole tablets (100 mg/day) for 14 days
Study: 18291275
Drug: Intraosseous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraosseous injection using the IntraFlow system
Study: 9021813
Drug: Propacetamol (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propacetamol (30 mg/kg)
Study: 9021813
Drug: Propacetamol (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propacetamol (15 mg/kg)
Study: 29379114
Drug: Cognitive remediation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive remediation (CR) plus a weekly goal-setting group
Study: 22939029
Drug: Compensatory cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compensatory cognitive training + standard pharmacotherapy
Study: 19165785
Drug: Scaffolds with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaffolds with mTGase treatment
Study: 15955154
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate or budesonide, initial dose of 300, 400 or 600 microg/day, reduced to maintenance level of 200, 300 or 400 microg/day after stabilization.
Study: 11992983
Drug: Relaxation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxation therapy for eight weeks
Study: 8109759
Drug: mivacurium 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: mivacurium 0.2 mg/kg, IV (Group II)
Study: 8109759
Drug: succinylcholine 1
Normalized name: Succinylcholine 124 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: succinylcholine 1 mg/kg, IV (Group I)
Study: 8109759
Drug: mivacurium 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: mivacurium 0.2 mg/kg, IV (Group III)
Study: 8109759
Drug: neostigmine 2.5
Normalized name: neostigmine 2.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: neostigmine 2.5 mg and glycopyrrolate 0.5 mg, IV (Group III)
Study: 23550856
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ISDN) 40 mg, repeated after 4 h as needed
Study: 23550856
Drug: Misoprostol 25
Normalized name: Misoprostol 25 microgram vaginal tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol 25 μg, repeated after 4 h as needed
Study: 21334136
Drug: PSA <3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSA <3.0 ng/ml screening
Study: 15562900
Drug: Amoxicillin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (10 days)
Study: 9778071
Drug: Fosinopril 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosinopril 5 to 20 mg every day
Study: 9778071
Drug: Enalapril 5
Normalized name: enalapril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 5 to 20 mg every day
Study: 7609497
Drug: Lacidipine 4
Normalized name: lacidipine 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacidipine 4 mg once daily for 1 week
Study: 7609497
Drug: Nifedipine 20
Normalized name: nifedipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 20 mg twice daily for 1 week
Study: 31308627
Drug: Pregabalin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (150 mg) and celecoxib (200 mg) 2 hrs before surgery
Study: 10374092
Drug: No preoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: No preoperative treatment
Study: 18158076
Drug: G +
Normalized name: Citracal 250 mg + D
Approvals — FDA: no, EMA: no, PMDA: no
Description: G + Met
Study: 17178796
Drug: Entecavir (ETV)
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Entecavir (ETV) 1.0 mg
Study: 11786772
Drug: Ropivacaine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine (40 ml of 0.75 percent)